Clinical Trial

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-11-19; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT07247110
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm
Enrollment 250 participants
Start Date 2025-12-16
Primary Completion 2030-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10